Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT05260619
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Please Select, Korea, Republic of
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 750
- Registration Number
- NCT05257083
- Locations
- 🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸UC San Diego Health Moores Cancer Center, San Diego, California, United States
Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 220
- Registration Number
- NCT05248633
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 1572
- Registration Number
- NCT05243797
- Locations
- 🇧🇷
IDOR- Instituto D'or de pesquisa. Av. São Rafael, Salvador, Brazil
🇧🇷Departamento de Oncologia Clínica AC Camargo Cancer Center, São Paulo, Brazil
🇧🇷Hemocentro UNICAMP, Universidade Estadual de Campinas, São Paulo, Brazil
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
- Conditions
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 53
- Registration Number
- NCT05222555
- Locations
- 🇨🇿
Vseobecna Fakultni Nemocnice V Praze, Praha, Czechia
🇨🇿Fakultni nemocnice v Motole, Praha, Czechia
🇨🇿Fakultni nemocnice Kralovske Vinohrady, Praha, Czechia
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT05211336
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
- Conditions
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Epizyme, Inc.
- Registration Number
- NCT05205252
- Locations
- 🇺🇸
Central Care Cancer Center, Bolivar, Missouri, United States
🇺🇸California Cancer Associates For Research And Excellence, cCARE, Santa Fe, California, United States
🇺🇸Astera Cancer Center, East Brunswick, New Jersey, United States
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 49
- Registration Number
- NCT05201248
- Locations
- 🇨🇳
Tianjin Cancer Hospital /ID# 228135, Tianjin, Tianjin, China
🇨🇳Peking University Third Hospital /ID# 228138, Beijing, Beijing, China
🇨🇳The Fifth Medical Center of PLA General Hospital /ID# 230520, Beijing, Beijing, China
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2022-03-11
- Target Recruit Count
- 36
- Registration Number
- NCT05200312
- Locations
- 🇨🇳
First affiliation hospital of nanjing medical university, Nanjing, Jiangsu, China
🇨🇳Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjin, Jiangsu, China
A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Takeda
- Registration Number
- NCT05183139
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.